Wednesday, January 18, 2023

Drug alert: 70 out of 1375 samples declared as NSQ in December 2022
Download the list of NSQ samples for December 2022, the link is given below: The Central Drugs Standard Control Organisation (CDSCO) has declared 70 drug samples out of a total of 1375 drug samples tested as not of standard quality (NSQ) and none as misbranded or spurious during the month of December 2022.

Click here to download NSQ list December 2022

Out of the 1375 samples tested during the month, 1305 samples came out with standard quality, while 70 samples were declared as not of standard quality (NSQ) & none declared as misbranded, and none as spurious.

Picture: Pixabay

None of the samples were identified as spurious and none declared as adulterated during the month. Every month, the drug regulator comes up with a list of drugs, medical devices, and cosmetics that are declared not of standard quality / spurious / adulterated / misbranded, every month.

Click to download month and year wise lists of NSQ drugs

During the month of November 2022, the authorities tested 1487 samples, out of which 1404 samples were tested as of standard quality. The number of samples declared as not of standard quality was 83 and none as misbranded and none as spurious.

During the month of October 2022, the authorities tested 1280 samples, out of which 1230 samples were tested as of standard quality. The number of samples declared as not of standard quality was 50 and none as misbranded and none as spurious.

During the month of September, 2022, the authorities tested 1456 samples, out of which 1397 samples were tested as of standard quality. The number of samples declared as not of standard quality was 59 and none as misbranded and none as spurious.

During the month of August, 2022, the authorities tested 1330 samples, out of which 1285 samples were tested as of standard quality. The number of samples declared as not of standard quality was 45 and none as misbranded and none as spurious.

During the month of July, 2022, the authorities tested 1337 samples, out of which 1283 samples were tested as of standard quality. The number of samples declared as not of standard quality was 53 and one as misbranded and none as spurious.

During the month of June, 2022, the authorities tested 1096 samples, out of which 1070 samples were tested as of standard quality. The number of samples declared as not of standard quality was 26 and none as misbranded and spurious.

During the month of May, 2022, the authorities tested 1233 samples, out of which 1192 samples were tested as of standard quality. The number of samples declared as not of standard quality was 41 and none as misbranded and spurious.

During the month of April, 2022, the authorities tested 1164 samples, out of which 1137 samples were tested as of standard quality. The number of samples declared as not of standard quality was 27 and none as misbranded and spurious.

During the month of March, 2022, the authorities tested 1454 samples, out of which 1406 samples were tested as of standard quality. The number of samples declared as not of standard quality was 48 and none as misbranded.

The test samples were drawn by the zonal and sub-zonal offices of CDSCO, and tested in the drug testing laboratories i.e CDL, CDTLs & RDTLs in Kolkata, Mumbai, Hyderabad, Chandigarh, and Guwahati.

Month wise drug alerts, click to download below links

Drug alert: 83 out of 1487 samples declared as NSQ in November 2022

Drug alert: 50 out of 1280 samples declared as NSQ in October 2022

Drug alert: 59 out of 1456 samples declared as NSQ in September 2022

Drug alert: 45 out of 1330 samples declared as NSQ in August 2022

Drug alert: 53 out of 1337 samples declared as NSQ in July 2022

Drug alert: 26 out of 1096 samples declared as NSQ in June 2022

Drug alert: 41 out of 1233 samples declared as NSQ in May 2022

Drug alert: 27 out of 1164 samples declared as NSQ in April 2022

Drug alert: 48 out of 1454 samples declared as NSQ in March 2022

Drug alert: 40 out of 1221 samples declared as NSQ in February 2022

Medical Device Alert: Lists

Safety alerts issued by IPC

Commercial Testing Laboratories

Govt Laboratories

Medical Devices Testing Laboratories (MDTLs)

List of Laboratory instruments

NABL

Latest Notifications: Testing Laboratories

USFDA gives tentative approval for Dolutegravir and Rilpivirine tablets

DCGI approves Covovax as booster dose

USFDA gives tentative approval for Levomilnacipran extended-release capsules

IPC includes dissolution test in IP: Read details

NPPA fixes retail price of 12 formulations: January 2023

Drug recall: Epinephrine API recalled due to this reason

NPPA revised Retail Price of 93 scheduled formulations: January 2023

Tramadol: 3 Pharmaceutical Companies under scanner

NABL suspends accreditation of 80 laboratories

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2023/01/18/drug-alert-70-out-of-1375-samples-declared-as-nsq-in-december-2022/
Drug alert: 70 out of 1375 samples declared as NSQ in December 2022
Download the list of NSQ samples for December 2022, the link is given below: The Central Drugs Standard Control Organisation (CDSCO) has declared 70 drug samples out of a total of 1375 drug samples tested as not of standard quality (NSQ) and none as misbranded or spurious during the month of December 2022.

Click here to download NSQ list December 2022

Out of the 1375 samples tested during the month, 1305 samples came out with standard quality, while 70 samples were declared as not of standard quality (NSQ) & none declared as misbranded, and none as spurious.

Picture: Pixabay

None of the samples were identified as spurious and none declared as adulterated during the month. Every month, the drug regulator comes up with a list of drugs, medical devices, and cosmetics that are declared not of standard quality / spurious / adulterated / misbranded, every month.

Click to download month and year wise lists of NSQ drugs

During the month of November 2022, the authorities tested 1487 samples, out of which 1404 samples were tested as of standard quality. The number of samples declared as not of standard quality was 83 and none as misbranded and none as spurious.

During the month of October 2022, the authorities tested 1280 samples, out of which 1230 samples were tested as of standard quality. The number of samples declared as not of standard quality was 50 and none as misbranded and none as spurious.

During the month of September, 2022, the authorities tested 1456 samples, out of which 1397 samples were tested as of standard quality. The number of samples declared as not of standard quality was 59 and none as misbranded and none as spurious.

During the month of August, 2022, the authorities tested 1330 samples, out of which 1285 samples were tested as of standard quality. The number of samples declared as not of standard quality was 45 and none as misbranded and none as spurious.

During the month of July, 2022, the authorities tested 1337 samples, out of which 1283 samples were tested as of standard quality. The number of samples declared as not of standard quality was 53 and one as misbranded and none as spurious.

During the month of June, 2022, the authorities tested 1096 samples, out of which 1070 samples were tested as of standard quality. The number of samples declared as not of standard quality was 26 and none as misbranded and spurious.

During the month of May, 2022, the authorities tested 1233 samples, out of which 1192 samples were tested as of standard quality. The number of samples declared as not of standard quality was 41 and none as misbranded and spurious.

During the month of April, 2022, the authorities tested 1164 samples, out of which 1137 samples were tested as of standard quality. The number of samples declared as not of standard quality was 27 and none as misbranded and spurious.

During the month of March, 2022, the authorities tested 1454 samples, out of which 1406 samples were tested as of standard quality. The number of samples declared as not of standard quality was 48 and none as misbranded.

The test samples were drawn by the zonal and sub-zonal offices of CDSCO, and tested in the drug testing laboratories i.e CDL, CDTLs & RDTLs in Kolkata, Mumbai, Hyderabad, Chandigarh, and Guwahati.

Month wise drug alerts, click to download below links

Drug alert: 83 out of 1487 samples declared as NSQ in November 2022

Drug alert: 50 out of 1280 samples declared as NSQ in October 2022

Drug alert: 59 out of 1456 samples declared as NSQ in September 2022

Drug alert: 45 out of 1330 samples declared as NSQ in August 2022

Drug alert: 53 out of 1337 samples declared as NSQ in July 2022

Drug alert: 26 out of 1096 samples declared as NSQ in June 2022

Drug alert: 41 out of 1233 samples declared as NSQ in May 2022

Drug alert: 27 out of 1164 samples declared as NSQ in April 2022

Drug alert: 48 out of 1454 samples declared as NSQ in March 2022

Drug alert: 40 out of 1221 samples declared as NSQ in February 2022

Medical Device Alert: Lists

Safety alerts issued by IPC

Commercial Testing Laboratories

Govt Laboratories

Medical Devices Testing Laboratories (MDTLs)

List of Laboratory instruments

NABL

Latest Notifications: Testing Laboratories

USFDA gives tentative approval for Dolutegravir and Rilpivirine tablets

DCGI approves Covovax as booster dose

USFDA gives tentative approval for Levomilnacipran extended-release capsules

IPC includes dissolution test in IP: Read details

NPPA fixes retail price of 12 formulations: January 2023

Drug recall: Epinephrine API recalled due to this reason

NPPA revised Retail Price of 93 scheduled formulations: January 2023

Tramadol: 3 Pharmaceutical Companies under scanner

NABL suspends accreditation of 80 laboratories

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2023/01/18/drug-alert-70-out-of-1375-samples-declared-as-nsq-in-december-2022/
Drug alert: 83 out of 1487 samples declared as NSQ in November 2022
Download the list of NSQ samples for November 2022, the link is given below: The Central Drugs Standard Control Organisation (CDSCO) has declared 83 drug samples out of a total of 1404 drug samples tested as not of standard quality (NSQ) and none as misbranded or spurious during the month of November 2022.

Click here to download NSQ list November 2022

Out of the 1487 samples tested during the month, 1404 samples came out with standard quality, while 83 samples were declared as not of standard quality (NSQ) & none declared as misbranded, and none as spurious.

Picture: Pixabay

None of the samples were identified as spurious and none declared as adulterated during the month. Every month, the drug regulator comes up with a list of drugs, medical devices, and cosmetics that are declared not of standard quality / spurious / adulterated / misbranded, every month.

Click to download month and year wise lists of NSQ drugs

During the month of October 2022, the authorities tested 1280 samples, out of which 1230 samples were tested as of standard quality. The number of samples declared as not of standard quality was 50 and none as misbranded and none as spurious.

During the month of September, 2022, the authorities tested 1456 samples, out of which 1397 samples were tested as of standard quality. The number of samples declared as not of standard quality was 59 and none as misbranded and none as spurious.

During the month of August, 2022, the authorities tested 1330 samples, out of which 1285 samples were tested as of standard quality. The number of samples declared as not of standard quality was 45 and none as misbranded and none as spurious.

During the month of July, 2022, the authorities tested 1337 samples, out of which 1283 samples were tested as of standard quality. The number of samples declared as not of standard quality was 53 and one as misbranded and none as spurious.

During the month of June, 2022, the authorities tested 1096 samples, out of which 1070 samples were tested as of standard quality. The number of samples declared as not of standard quality was 26 and none as misbranded and spurious.

During the month of May, 2022, the authorities tested 1233 samples, out of which 1192 samples were tested as of standard quality. The number of samples declared as not of standard quality was 41 and none as misbranded and spurious.

During the month of April, 2022, the authorities tested 1164 samples, out of which 1137 samples were tested as of standard quality. The number of samples declared as not of standard quality was 27 and none as misbranded and spurious.

During the month of March, 2022, the authorities tested 1454 samples, out of which 1406 samples were tested as of standard quality. The number of samples declared as not of standard quality was 48 and none as misbranded.

During the month of February, 2022, the authorities tested 1221 samples, out of which 1181 samples were tested as of standard quality. The number of samples declared as not of standard quality was 39 and one as misbranded.

The test samples were drawn by the zonal and sub-zonal offices of CDSCO, and tested in the drug testing laboratories i.e CDL, CDTLs & RDTLs in Kolkata, Mumbai, Hyderabad, Chandigarh, and Guwahati.

Month wise drug alerts, click to download below links

Drug alert: 50 out of 1280 samples declared as NSQ in October 2022

Drug alert: 59 out of 1456 samples declared as NSQ in September 2022

Drug alert: 45 out of 1330 samples declared as NSQ in August 2022

Drug alert: 53 out of 1337 samples declared as NSQ in July 2022

Drug alert: 26 out of 1096 samples declared as NSQ in June 2022

Drug alert: 41 out of 1233 samples declared as NSQ in May 2022

Drug alert: 27 out of 1164 samples declared as NSQ in April 2022

Drug alert: 48 out of 1454 samples declared as NSQ in March 2022

Drug alert: 40 out of 1221 samples declared as NSQ in February 2022

Drug alert: 27 out of 1227 samples declared as NSQ in January 2022

Medical Device Alert: Lists

Safety alerts issued by IPC

Commercial Testing Laboratories

Govt Laboratories

List of Laboratory instruments

Latest Notifications: Testing Laboratories

FDA: Patients cannot be forced to buy medicines from hospital-attached pharmacies

Pharmacy education needs to adopt 2D, 3D format for lectures

Indian Pharma Companies have potential in Saudi Arabia

USFDA gives nod for Silodosin, Pregabalin Capsules

Parliament panel recommendation for National Commission on Medical Devices

Homoeopathy: Commission notifies BHMS Regulations 2022

USFDA gives final approval for Desonide cream

Gujarat sets up new 784 manufacturing units during the last one year

National roundtable on safe Blood Transfusions

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/12/13/drug-alert-83-out-of-1487-samples-declared-as-nsq-in-november-2022/
Drug Alert: NSQ Drugs Lists - Updated
Download the lists of NSQ drugs given below: We have provided the list of "not of standard quality" (NSQ) drugs declared by various drug testing laboratories in India.

Picture: Pixabay

Lists of NSQ drugs

2022

December 2022: Download the list of NSQ samples, click below link:

Drug-Alert-December-2022

November 2022: Download the list of NSQ samples, click below link:

Drug-Alert-November-2022

October 2022 (Revised): Download the list of NSQ samples, click below link:

Drug-Alert-October-2022-Revised

October 2022: Download the list of NSQ samples, click below link:

Drug-Alert-October-2022

September 2022: Download the list of NSQ samples, click below link:

Drug-Alert-September-2022

August 2022: Download the list of NSQ samples, click below link:

Drug-Alert-list-August-2022

July 2022: Download the list of NSQ samples, click below link:

Drug-Alert-list-July-2022

June 2022: Download the list of NSQ samples, click below link:

Drug-Alert-list-June-2022

May 2022 (Revised): Download the list of NSQ samples, click below link:

Drug-Alert-list-May-2022-Revised

May 2022: Download the list of NSQ samples, click below link:

Drug-Alert-List-May-2022

April 2022 (Revised): Download the list of NSQ samples, click below link:

Drug-Alert-list-April-2022-Revised

April 2022: Download the list of NSQ samples, click below link:

Drug-Alert-list-April-2022

March 2022: Download the list of NSQ samples, click below link:

Drug-Alert-list-March-2022

February 2022 (Revised): Download the list of NSQ samples, click below link:

Drug-Alert-February-2022-Revised

February 2022: Download the list of NSQ samples, click below link:

Drug-Alert-List-February-2022

January 2022: Download the list of NSQ samples, click below link:

Drug-Alert-List-January-2022

2021

December 2021: Download the list of NSQ samples, click below link:

Drug-Alert-List-December-2021

November 2021: Download the list of NSQ samples, click below link:

Drug-Alert-List-November-2021

October 2021: Download the list of NSQ samples, click below link:

Drug-Alert-List-October-2021

September 2021: Download the list of NSQ samples, click below link:

Drug-Alert-List-September-2021

August 2021: Download the list of NSQ samples, click below link:

Drug-Alert-List-August-2021

July 2021: Download the list of NSQ samples, click below link:

Drug-Alert-List-July-2021

June 2021: Download the list of NSQ samples, click below link:

Drug-Alert-List-June-2021

May 2021: Download the list of NSQ samples, click below link:

Drug-Alert-List-May-2021

April 2021: Download the list of NSQ samples, click below link:

Drug-Alert-List-April-2021

March 2021: Download the list of NSQ samples, click below link:

Drug-Alert-List-March-2021

February 2021: Download the list of NSQ samples, click below link:

Drug-Alert-List-February-2021

January 2021: Download the list of NSQ samples, click below link:

Drug-Alert-List-January-2021

2020

December 2020: Download the list of NSQ samples, click below link:

Drug-Alert-List-December-2020

November 2020: Download the list of NSQ samples, click below link:

Drug-Alert-List-November-2020

October 2020: Download the list of NSQ samples, click below link:

Drug-Alert-List-October-2020

September 2020: Download the list of NSQ samples, click below link:

Drug-Alert-List-September-2020

August 2020: Download the list of NSQ samples, click below link:

Drug-Alert-List-August-2020

July 2020: Download the list of NSQ samples, click below link:

Drug-Alert-List-July-2020

June 2020: Download the list of NSQ samples, click below link:

Drug-Alert-List-June-2020

May 2020: Download the list of NSQ samples, click below link:

Drug-Alert-List-May-2020

April 2020: Download the list of NSQ samples, click below link:

Drug-Alert-List-April-2020

March 2020: Download the list of NSQ samples, click below link:

Drug-Alert-List-March-2020

February 2020: Download the list of NSQ samples, click below link:

Drug-Alert-List-February-2020

January 2020: Download the list of NSQ samples, click below link:

Drug-Alert-List-January-2020

2019

December 2019: Download the list of NSQ samples, click below link:

Drug-Alert-List-December-2019

November 2019: Download the list of NSQ samples, click below link:

Drug-Alert-List-November-2019

October 2019: Download the list of NSQ samples, click below link:

Drug-Alert-List-October-2019

Source of Drug alert lists: CDSCO website

Medical Device Alert: Lists

Safety alerts issued by IPC

Commercial Testing Laboratories

Govt Laboratories

List of Laboratory instruments

Latest Notifications: Testing Laboratories

Click to read other articles of the Author

Licensing procedure for manufacturing of Drugs

Procedure to obtain license for manufacturing of Cosmetics

Procedure to obtain license for manufacturing of Homoeopathic Medicines

Procedure to obtain license for manufacturing of Medical Devices

Procedure to obtain License to Manufacture drugs for testing and analysis purposes

Procedure to obtain license for Blood Centre (Blood Bank)

Procedure to obtain license for Commercial Testing Laboratories

Procedure to obtain license for Medical Store / Pharmacy

How to start Jan Aushadhi Store: Procedure

Click to read other articles of the Author
https://thehealthmaster.com/2022/09/15/drug-alert-nsq-drugs-lists-updated/
Drug Alert: NSQ Drugs Lists
Download the lists of NSQ drugs given below: We have provided the list of "not of standard quality" (NSQ) drugs declared by various drug testing laboratories in India.

Picture: Pixabay

Lists of NSQ drugs

2022

December 2022: Download the list of NSQ samples, click below link:

Drug-Alert-December-2022

November 2022: Download the list of NSQ samples, click below link:

Drug-Alert-November-2022

October 2022 (Revised): Download the list of NSQ samples, click below link:

Drug-Alert-October-2022-Revised

October 2022: Download the list of NSQ samples, click below link:

Drug-Alert-October-2022

September 2022: Download the list of NSQ samples, click below link:

Drug-Alert-September-2022

August 2022: Download the list of NSQ samples, click below link:

Drug-Alert-list-August-2022

July 2022: Download the list of NSQ samples, click below link:

Drug-Alert-list-July-2022

June 2022: Download the list of NSQ samples, click below link:

Drug-Alert-list-June-2022

May 2022 (Revised): Download the list of NSQ samples, click below link:

Drug-Alert-list-May-2022-Revised

May 2022: Download the list of NSQ samples, click below link:

Drug-Alert-List-May-2022

April 2022 (Revised): Download the list of NSQ samples, click below link:

Drug-Alert-list-April-2022-Revised

April 2022: Download the list of NSQ samples, click below link:

Drug-Alert-list-April-2022

March 2022: Download the list of NSQ samples, click below link:

Drug-Alert-list-March-2022

February 2022 (Revised): Download the list of NSQ samples, click below link:

Drug-Alert-February-2022-Revised

February 2022: Download the list of NSQ samples, click below link:

Drug-Alert-List-February-2022

January 2022: Download the list of NSQ samples, click below link:

Drug-Alert-List-January-2022

2021

December 2021: Download the list of NSQ samples, click below link:

Drug-Alert-List-December-2021

November 2021: Download the list of NSQ samples, click below link:

Drug-Alert-List-November-2021

October 2021: Download the list of NSQ samples, click below link:

Drug-Alert-List-October-2021

September 2021: Download the list of NSQ samples, click below link:

Drug-Alert-List-September-2021

August 2021: Download the list of NSQ samples, click below link:

Drug-Alert-List-August-2021

July 2021: Download the list of NSQ samples, click below link:

Drug-Alert-List-July-2021

June 2021: Download the list of NSQ samples, click below link:

Drug-Alert-List-June-2021

May 2021: Download the list of NSQ samples, click below link:

Drug-Alert-List-May-2021

April 2021: Download the list of NSQ samples, click below link:

Drug-Alert-List-April-2021

March 2021: Download the list of NSQ samples, click below link:

Drug-Alert-List-March-2021

February 2021: Download the list of NSQ samples, click below link:

Drug-Alert-List-February-2021

January 2021: Download the list of NSQ samples, click below link:

Drug-Alert-List-January-2021

2020

December 2020: Download the list of NSQ samples, click below link:

Drug-Alert-List-December-2020

November 2020: Download the list of NSQ samples, click below link:

Drug-Alert-List-November-2020

October 2020: Download the list of NSQ samples, click below link:

Drug-Alert-List-October-2020

September 2020: Download the list of NSQ samples, click below link:

Drug-Alert-List-September-2020

August 2020: Download the list of NSQ samples, click below link:

Drug-Alert-List-August-2020

July 2020: Download the list of NSQ samples, click below link:

Drug-Alert-List-July-2020

June 2020: Download the list of NSQ samples, click below link:

Drug-Alert-List-June-2020

May 2020: Download the list of NSQ samples, click below link:

Drug-Alert-List-May-2020

April 2020: Download the list of NSQ samples, click below link:

Drug-Alert-List-April-2020

March 2020: Download the list of NSQ samples, click below link:

Drug-Alert-List-March-2020

February 2020: Download the list of NSQ samples, click below link:

Drug-Alert-List-February-2020

January 2020: Download the list of NSQ samples, click below link:

Drug-Alert-List-January-2020

2019

December 2019: Download the list of NSQ samples, click below link:

Drug-Alert-List-December-2019

November 2019: Download the list of NSQ samples, click below link:

Drug-Alert-List-November-2019

October 2019: Download the list of NSQ samples, click below link:

Drug-Alert-List-October-2019

Source of Drug alert lists: CDSCO website

Medical Device Alert: Lists

Safety alerts issued by IPC

Medical Device Alert: Lists

Commercial Testing Laboratories

Govt Laboratories

List of Laboratory instruments

Latest Notifications: Testing Laboratories

Licensing procedure for manufacturing of Drugs

Procedure to obtain license for manufacturing of Cosmetics

Procedure to obtain license for manufacturing of Homoeopathic Medicines

Procedure to obtain license for manufacturing of Medical Devices

Procedure to obtain License to Manufacture drugs for testing and analysis purposes

Procedure to obtain license for Blood Centre (Blood Bank)

Procedure to obtain license for Commercial Testing Laboratories

Procedure to obtain license for Medical Store / Pharmacy

How to start Jan Aushadhi Store: Procedure
https://thehealthmaster.com/drug-alert-nsq-drugs-lists/

Tuesday, January 17, 2023

Govt Job: For Pharma Professionals at ICMR - Pay Rs. 70k pm
The Indian Council of Medical Research (ICMR), New Delhi, the apex body in India for the formulation, coordination and promotion of biomedical research, is one of the oldest medical research bodies in the world. 

The ICMR has always attempted to address itself to the growing demands of scientific advances in biomedical research on the one hand, and to the need of finding practical solutions to the health problems of the country, on the other.

The ICMR has come a long way from the days when it was known as the IRFA, but the Council is conscious of the fact that it still has miles to go in pursuit of scientific achievements as well as health targets.

Post : Consultant Scientific

A Walk-in interview will be conducted for the following position of Consultant Scientific for providing regulatory/clinical validation related consultancy support.

ICMR intends to engage following Non-Institutional Project Position, purely on temporary contract basis for its short-term research projects, being undertaken by the Medical Device and Diagnostic Mission Secretariat (MDMS) at ICMR HQ.

Number of Vacancy : One

Essential Qualifications : Professionals having M.Sc/B.Tech/M.Tech/MBA/M.Pharma/M.V.S./ Masters in Public Policy qualifications in relevant subject with research & development experience and published papers.

Desirable Qualifications : Knowledge/experience related to various healthcare initiatives of GoI. Including Ayushman Bharat Scheme, National Health Mission, Major pandemics and outbreaks management in India.

Qualified professional with established experience in management of government of India funding schemes, project management hands on experience of handling clinical validation of Medical Devices, Diagnostics etc. Experience in project Management will be an added advantage, knowledge on ISO 13485, Medical Device Rules-2017, ISO 14971, IEC 62304 etc.

Consolidated Emoluments : Up to Rs. 70,000/- depending upon education experience and knowledgeAge Limit : 70 Years

Tenure : One YearPlace of work : ICMR Hqrs

Other Information1) Candidates who wish to appear for the above mentioned post may download the application form from the websites of  main.icmr.nic.in. Candidates are requested to fill the application form and bring all the original certificates of educational qualification (Certificate/Statement of marks), experience certificates etc., along with one set of Xerox of the same duly self-attested and a recent passport size photograph for attending the Walk-in-written test/interview.

2) Age, Qualification, Experience etc., will be reckoned as on the date of Walk-in-Written Test /Interview.

3) Mere fulfilling the essential qualification does not guarantee for the selection.

4) Person already in regular time scale service under any Government Department/Organizations are not eligible to apply.

5) No TA/DA etc., will be paid to the candidate for appearing in Walk-in- Written test/interview.

6) The selected candidate will have no claim for regular appointment in any ICMR Institutes/ Centres for continuation of his/her services in any other project.

7) Any canvassing by or on behalf of the candidate or bringing political or other outside influence with regard to selection shall be a disqualification and such candidates will not be considered.

8) The Director-General has the right to accept/reject any application without assigning any reason(s) and no correspondence in this matter will be entertained.

9) The applicants are advised to visit our website regularly for any updates and changes in the recruitment.

General Instructions :-1) Candidates are required to be present at the venue in time and Walk-in Written Test/Interview will commence after verification of all the original certificates.

2) The offer of engagement will be subject to verification of original certificates as per the advertisement.

3) No calculators, log tables, communication devices like mobile phone, Tablet/iPad etc., are allowed inside the Examination/Interview Hall.

4) Request for re-evaluation of answer sheets will not be entertained.

5) Candidates who resort to malpractice of any kind will immediately be sent out of the Examination Hall.

6) The candidates attending the above Written test /Interview must follow COVID appropriate behaviours.

Date of Interview : 31st January, 2023

Place of Interview : Room No. 320, Second Floor, ICMR Hqrs

Application Form & More Info

CORRIGENDUM

Govt Job: For M.Pharm, M.Sc at CFSL | Pay upto Rs. 1,77,500 pm

Govt Job: For Ph.D, M.Pharm, M.Sc under Ministry of Science & Technology

Govt Job: For Pharma Research Associate at BITS

Govt Job: For M.Pharm, B.Pharm at NPPA

Govt Job: For Pharmacists under Ministry of Defence

Govt Job: For M.Pharm, M.Sc for IMR Research Project at CSMCARI
https://thehealthmaster.com/2023/01/17/govt-job-for-pharma-professionals-at-icmr-pay-rs-70k-pm/
Govt Job: For M.Pharm, M.Sc at CFSL | Pay upto Rs. 1,77,500 pm
The Union Public Service Commission, commonly abbreviated as UPSC, is India's premier central recruiting agency.

It is responsible for appointments to and examinations for All India Services and group A & group B of Central Services. The Department of Personnel and Training is the central personnel agency in India. 

The agency's charter is granted by Part XIV of the Constitution of India, titled as Services Under the Union and the States.

Post : Scientist ‘B’ (Toxicology)

No of posts : 01 (UR-01)Pay Scale : Level – 10 (Rs.56,100 – 1,77,500/-) in Pay Matrix as per CCS (R.P.) Rules, 2016. (Total emoluments excluding T.A. & HRA at the time of initial appointment will be Rs. 56,100 /- plus DA p.m. as applicable approximately)

Department / Office : Directorate of Forensic Science ServicesOrganisation : Central Forensic Science Laboratory

Essential Qualifications(A) Educational : Master Degree in Chemistry or Biochemistry or Pharmacology or Pharmacy or Forensic Science with Chemistry as one of the subjects during all the three years of bachelor of Science from a recognised University or institute.

(B) Experience : Three years experience of analytical methods and research therein in the field of Toxicology from a government recognised orgnization or institution.

Desirable : One year experience of working in a Forensic Science Laboratory under the Central or State Government or Union Territory administration after obtaining the minimum prescribed educational qualifications. 

Note : The Qualifications are relaxable at the discretion of the Union Public Service Commission, for reasons to be recorded in writing, in the case of candidates otherwise well qualified.

Duties : Crime Case Examination, giving evidences in the Court of Law, Crime Scene Examination, providing guidance to the junior scientific staff for case analysis, R&D activities on Forensic Science and imparting training in the respective field of forensic specialization to the trainees from different investigating agencies / forensic science labs and other organizations.

Headquarters : New Delhi with Laboratories at Chandigarh, Kolkata, Hyderabad, Pune, Kamrup (Assam) & Bhopal. In connection with performing the duties, the officer may be required to serve in any part of India.

Any Other Condition :(i) Leprosy Cured persons are suitable for the post of Scientist ‘B’ (Toxicology) in CFSLs subject to the condition that their upper limbs are functioning normally.(ii) Acid attack victims are suitable for the post of Scientist ‘B’ (Toxicology) in CFSLs provided that their vision and hearing have not been impaired.

INSTRUCTIONS AND ADDITIONAL INFORMATION TO CANDIDATES FOR RECRUITMENT BY SELECTION1. CITIZENSHIP: A Candidate must be either: (a) a citizen of India, or (b) a subject of Nepal, or (c) a subject of Bhutan, or (d) a Tibetan refugee who came over to India before 1 st January, 1962 with the intention of permanently settling in India, or (e) a person of Indian origin who has migrated from Pakistan, Burma, Sri Lanka or East African countries of Kenya, Uganda, the United Republic of Tanzania(formerly Tanganyika and Zanzibar), Zambia, Malawi, Zaire, Ethiopia and Vietnam with the intention of permanently settling in India.

Provided that a candidate belonging to categories (b), (c), (d) and (e) above shall be a person in whose favour a certificate of eligibility has been issued by the Government of India.

NOTE The application of a candidate in whose case a certificate of eligibility is necessary, may be considered by the Commission and, if recommended for appointment, the candidate may also be provisionally appointed subject to the necessary certificate being issued in his favour by the Government of India.

2. AGE LIMITS: The age limit for the post has been given in the advertisement. For certain age concessions admissible to various categories please go through the instruction regarding Concessions & Relaxations.

3. MINIMUM ESSENTIAL QUALIFICATIONS: All applicants must fulfill the essential requirements of the post and other conditions stipulated in the advertisement.

They are advised to satisfy themselves before applying that they possess at least the essential qualifications laid down for various posts. No enquiry asking for advice as to eligibility will be entertained.

NOTE-I : The prescribed essential qualifications are the minimum and the mere possession of the same does not entitle candidates to be called for interview.

APPLICATION FEE(a) Candidates are required to pay a fee of Rs. 25/- (Rupees Twenty five) only either by remitting the money in any branch of the SBI by cash or by using net banking facility of the SBI or by using visa/master credit/debit card.

(b) No fee for SC/ST/PwBD/Women candidates of any community. No "fee exemption" is available to Gen/OBC/EWS male candidates and they are required to pay the full prescribed fee.

(c) Applications without the prescribed fee would not be considered and summarily rejected. No representation against such rejection would be entertained.

(d) Fee once paid shall not be refunded under any circumstance nor can the fee be held in reserve for any other examination or selection

HOW TO APPLYi) Candidates must apply online through the website http://www.upsconline.nic.in. Applications received through any other mode would not be accepted and summarily rejected.

ii) Candidates must upload the documents/certificates in support of all the claims made by them in the application like, Date of Birth, Experience (preferably in prescribed format), Desirable Qualification(s) etc. or any other information, separately against each claim in pdf file in such a way that the file size does not exceed 1 MB for the respective aforesaid modules and 2 MB for the “UPLOAD OTHER DOCUMENT” module and is legible when a printout taken.

For that purpose, the applicant may scan the documents/certificates in 200 dpi grey scale. Documents like Pay Slip, Resume, Appointment Letter, Relieving Letter, Un-signed Experience Certificate etc. must not be uploaded in the Document Upload Module:-

a) Matriculation/10th Standard or equivalent certificate indicating date of birth, or mark sheet of Matriculation/10th Standard or equivalent issued by Central/State Board indicating Date of Birth in support of claim of age. Where date of birth is not available in certificate/mark sheets, issued by concerned Educational Boards, School leaving certificate indicating Date of Birth (in case of Tamil Nadu& Kerala).

b) Degree/Diploma certificate as proof of educational qualification claimed. In the absence of Degree/Diploma certificate, provisional certificate along with mark sheets pertaining to all the academic years.

c) Order/ letter in respect of equivalent Educational Qualifications claimed, indicating the Authority (with number and date) under which it has been so treated, in respect of equivalent clause in Essential Qualifications, if a candidate is claiming a particular qualification as equivalent qualification as per the requirement of advertisement.

d) Certificate(s) in the prescribed proforma from the Head(s) of Organization(s)/Department(s) for the entire experience claimed, clearly mentioning the duration of employment (date, month & year) indicating the basic pay and consolidated pay.

The certificate(s) should also mention the nature of duties performed/experience obtained in the post(s) with duration(s).

Experience Certificate should be issued in prescribed format relevant to the post. Experience certificate not in prescribed proforma but containing all the details as mentioned above would be considered on merits by the Commission.

e) Caste certificate by candidate seeking reservation as SC/ ST/ OBC, in the prescribed proforma from the competent authority indicating clearly the candidate’s Caste, the Act/ Order under which the Caste is recognized as SC/ ST/ OBC and the village/ town the candidate is ordinarily a resident of.

f) A declaration in the prescribed format by candidate seeking reservation as OBC, that he/she does not belong to the creamy layer on the crucial date, in addition to the community certificate (OBC).

Unless specified otherwise, the prescribed closing date for receipt of Online Recruitment Application for the post is to be treated as crucial date.

g) Certificate of Disability in prescribed proforma issued by the competent authority to Persons with Benchmark Disabilities (PwBD) eligible for appointment to the post on the basis of prescribed standards of Medical Fitness.

The Competent Authority to issue Certificate of Disability shall be a Medical Board duly constituted by the Central or a State Government.

The Central/ State Government may constitute Medical Board(s) consisting of at least three members out of which at least one shall be a specialist in the particular field for assessing Locomotor/ Cerebral / Visual / Hearing disability, as the case may be.

h) Documentary support for any other claim(s) made.

Note: If any document/ certificate furnished is in a language other than Hindi or English, a transcript of the same duly attested by a Gazetted officer or notary is to be uploaded.

iii) IMPORTANT : CANDIDATES ARE ADVISED TO FILL THEIR CORRECT AND ACTIVE E-MAIL ADDRESSES IN THE ONLINE APPLICATION AS ALL CORRESPONDENCE WILL BE MADE BY THE COMMSSION THROUGH E-MAIL ONLY. INTERVIEW SCHEDULE AND REQUIREMENTS WITH REGARD TO COPIES OF CERTIFCATES TO BE SUBMITTED IN RESPECT OF CLAIMS MADE IN THE ONLINE APPLICATION WILL BE E-MAILED IN DUE COURSE TO THE CANDIDATES IN THEIR REGISTERED E-MAIL ID AND WILL ALSO BE POSTED ON THE WEBSITE OF THE COMMISSION.

iv) Candidates who wish to apply for more than one post should apply separately for each post and pay the fee for each post in the prescribed manner.

v) After submitting the Online Recruitment Application (ORA), the candidates are required to take out a print out of the finally submitted Online Recruitment Application.

vi) Candidates are not required to submit to the Commission either by post or by hand the printouts of their online applications or any other document.

They will be required to bring along with them the printouts of their online applications and the documents mentioned in para 7 below if called for interview.

vii) The applicants are advised to submit only single Online Recruitment Application for each post; however, if somehow, if he/she submits multiple Online Recruitment Applications for one post, then he/she must ensure that Online Recruitment Application with the higher "Application Number" is complete in all respects including fee.

The applicants, who submit multiple Online Recruitment Applications, should note that only the Online Recruitment Application with higher "Application Number" shall be entertained by the Commission and fee paid against one "Application Number" shall not be adjusted against any other "Application Number".

viii) The candidates are advised to submit the Online Recruitment Application well in advance without waiting for the closing date.

OTHER INFORMATION/INSTRUCTIONSa) All candidates whether in Government service or in Government owned industrial or other similar organizations or in private employment should submit their applications online directly to the Commission.

Persons already in Regular Government service, whether in permanent or temporary capacity other than casual/adhoc/daily wages/hourly paid/contract basis are however required to submit a declaration that they have informed in writing to their Head of Office/Department that they have applied for the selection.

b) The date for determining the eligibility of all candidates in every respect shall be the closing date for submitting the Online Recruitment Application on the website upsconline.nic.in.

c) In respect of equivalent clause in Essential Qualifications, if a candidate is claiming a particular qualification as equivalent qualification as per the requirement of advertisement, then the candidate is required to produce order/letter in this regard, indicating the Authority (with number and date) under which it has been so treated otherwise the Online Recruitment Application is liable to be rejected.

d) Candidates must, if required, attend a personal interview at such place, as may be fixed by the Commission. The Commission do not defray the traveling or other expenses of candidates summoned for interview.

They, however, contribute towards those expenses at a rate corresponding to the amount of the Second Class Mail railway fare by the shortest route to the place of interview from the Railway Station nearest to the normal place of residence of the candidate or from which he actually performs the journey, whichever, is nearer to the place of interview, and back to the same station or the amount of Railway fare actually incurred by the candidate whichever is less. Details of this will be furnished when they are called for interview.

e) Commission’s contribution towards the traveling expenses in respect of those candidates who are interviewed at Delhi will be paid on the spot on the date of interview itself provided they fulfill all the conditions.

In respect of those candidates who have been called to be present at interviews at places other than Delhi, the same will be sent by Money Order later on.

Candidates who do not wish to collect contribution towards TA in cash at Commission’s counter can also get the same transferred in their respective account.

Such candidates will have to submit a cancelled cheque along with their TA claims to facilitate the transaction’.

f) The Summoning of candidates for interview convey no assurance whatsoever that they will be selected. Appointment orders to selected candidates will be issued by the Government.

g) Candidates must be in sound bodily health. They must, if selected be prepared to undergo such medical examination and satisfy such medical authority as Government may require.

h) Candidates will be informed of the final result in due course through UPSC website/ Employment News and any interim enquiries about the result are therefore, unnecessary and will not be attended to.

The Commission do not enter into correspondence with the candidates about reasons for their non selection for interview/appointment.

i) The Commission may grant higher initial pay to candidates adjudged meritorious in the interview.

j) Canvassing in any form will disqualify a candidate.

Last Date :02.02.2023

Vacancy Number : 23010109214

Apply Online

Govt Job: For Ph.D, M.Pharm, M.Sc under Ministry of Science & Technology

Govt Job: For Pharma Research Associate at BITS

Govt Job: For M.Pharm, B.Pharm at NPPA

Govt Job: For Pharmacists under Ministry of Defence

Govt Job: For M.Pharm, M.Sc for IMR Research Project at CSMCARI

Govt Job: For Lecturers in Pharmacy institute under ME&RD
https://thehealthmaster.com/2023/01/16/govt-job-for-m-pharm-m-sc-at-cfsl-pay-upto-rs-177500-pm/
USFDA gives tentative approval for Dolutegravir and Rilpivirine tablets
The United States Food and Drug Administration (USFDA) has given tentative approval to Lupin for its Abbreviated New Drug Application (ANDA), Dolutegravir and Rilpivirine tablets, 50 mg/25 mg, to market a generic equivalent of Juluca tablets, 50 mg/25 mg of ViiV Healthcare, a statement from the company notified yesterday.

The tablets are used to treat HIV infection.
https://thehealthmaster.com/2023/01/17/usfda-gives-tentative-approval-for-dolutegravir-and-rilpivirine-tablets/
DCGI approves Covovax as booster dose
The Drug Controller General of India (DCGI) has approved market authorisation to COVID-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said yesterday.

The DCGI’s approval came following recommendation by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).

Prakash Kumar Singh, Director, Government and Regulatory Affairs, Serum Institute of India (SII), had recently written to the DCGI for the approval of Covovax heterologous booster dose for those aged 18 years and above in view of the escalating COVID-19 pandemic situation in some countries, an official source had said.

The SEC of the CDSCO recently deliberated on the issue and had recommended for market authorisation of COVID jab Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, according to an official source.

The DCGI had approved Covovax for restricted use in emergency situations in adults on 28th December, 2021, in the 12-17 years age group on 9th March, 2022, and in children aged 7-11 years on 28th June last year subject to certain conditions.

Covovax is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency (EMA) for conditional marketing authorisation.

It was granted Emergency Use Listing (EUL) by the World Health Organization (WHO) on 17th December, 2021.

In August 2020, the United States (US)-based vaccine maker Novavax had announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373, its COVID-19 vaccine candidate in India and in Low-and-Middle-Income Countries (LMICs).
https://thehealthmaster.com/2023/01/17/dcgi-approves-covovax-as-booster-dose/
The Drug Controller General of India (DCGI) has approved market authorisation to COVID-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said yesterday.

The DCGI’s approval came following recommendation by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).

Prakash Kumar Singh, Director, Government and Regulatory Affairs, Serum Institute of India (SII), had recently written to the DCGI for the approval of Covovax heterologous booster dose for those aged 18 years and above in view of the escalating COVID-19 pandemic situation in some countries, an official source had said.

The SEC of the CDSCO recently deliberated on the issue and had recommended for market authorisation of COVID jab Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, according to an official source.

The DCGI had approved Covovax for restricted use in emergency situations in adults on 28th December, 2021, in the 12-17 years age group on 9th March, 2022, and in children aged 7-11 years on 28th June last year subject to certain conditions.

Covovax is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency (EMA) for conditional marketing authorisation.

It was granted Emergency Use Listing (EUL) by the World Health Organization (WHO) on 17th December, 2021.

In August 2020, the United States (US)-based vaccine maker Novavax had announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373, its COVID-19 vaccine candidate in India and in Low-and-Middle-Income Countries (LMICs).
https://thehealthmaster.com/2023/01/17/dcgi-approves-covovax-as-booster-dose/
Guidance document: monographs for Indian Pharmacopoeia: IPC
The Indian Pharmacopoeia Commission (IPC) has released the Guidance Document for Drafting and Formatting of Monographs for Indian Pharmacopoeia (IP) to guide the stakeholders including drug manufacturers, analysts and academicians on drafting of drug monographs before their inclusion in the Indian Pharmacopoeia.

In this Guidance Document, emphasis has been given to elaborate IP monographs under the categories of active pharmaceutical ingredients (APIs), dosage forms, pharmaceutics.

To read or download the above guidance document, click here

IP is a compilation of official standards for drugs manufactured and/or marketed in India. A monograph states the quality or test parameters, the acceptance criteria and details of the tests that are to be performed to determine compliance with the criteria.

Picture: Pixabay

In other words, a pharmacopoeial monograph provides a reliable basis for making an independent and objective judgement as to the quality of a pharmaceutical substance.

As IP standards are statutory, it is important that the contents of monographs are unambiguous, acceptance criteria are clearly spelt out and the methods of evaluation provide all the details for carrying out the tests and assays, including the equipment, reagents and other ancillary materials that are to be used.

Also read:

Drugs & Cosmetics Act should be renamed as MMDTC Act, 2021

Govt appoints Dr Rajeev Singh as Secretary / Scientific Director of IPC

IP 2018: IPC to amend monographs of vaccines & immunosera

Phytopharmaceuticals: IPC invites suggestions from stakeholders

The guidance document is a guide for drafting and elaboration of the monographs to the stakeholders of the IP especially industries, testing laboratories and academicians. The aim is to provide guidance for drafting clear unambiguous texts, with similar requirements presented in the same way in each monograph.

The technical part of pharmacopoeia shall be broadly divided into the following sections like introduction, general chapters, reference data, general tests and general notices.

The scientific director of the Indian Pharmacopoeia Commission shall approve this part after all the contents of the pharmacopoeia have been finalised. It shall briefly give the background to the edition and describe the salient features including the admissions and omissions from the previous edition.

The guidance document bears a lot of relevance as there is a need for regular updation of IP to meet essential requirements for harmonisation of analytical methods in IP with those accepted internationally keeping in view Indian scenario.

Read more about IPC:

Indian Pharmacopoeia Commission (IPC)

IPC-19-02-2021-Release-of-Guidance-Document-for-Drafting-and-Formatting-of-Monographs-for-Indian-Pharmacopoeia

IPC-dt-12-01-2021-Draft-of-General-Notices-on-Phytopharmaceutical-Drugs

List-of-145-Impurities-Dec-2019

List-of-594-Reference-Substances-Dec-2019

Latest Circulars: (IPC) Indian Pharmacopoeia Commission

Latest Notifications regarding Pharmaceuticals

Latest on National Formulary of India (NFI)

Safety alerts issued by IPC

Online purchase: procedure

Books: IP and NFI

Rates-and-Procedure-to-purchase-of-different-volumes-of-IP-and-NFI

Click here to purchase Books: IP & NFI

IP Reference Substances

Click here to purchase IP Reference Substances

Impurity Standards

Click here to purchase Impurity Standards

Monographs

Pharmaceuticals Monograph

Click here for Pharmaceuticals Monograph

Veterinary Monograph

Click here for Veterinary Monograph
https://thehealthmaster.com/2021/02/23/guidance-document-monographs-for-indian-pharmacopoeia-ipc/

Saturday, January 14, 2023

Artificial sweetener in diet products linked to anxiety: Must read
Aspartame, an artificial sweetener included in approximately 5,000 diet goods and beverages, has been linked by Florida State University College of Medicine researchers to anxiety-like behavior in mice.

In addition to causing anxiety in the mice who consumed aspartame, the effects of the sweetener extended up to two generations from the males exposed to it.

The study is published in the Proceedings of the National Academy of Sciences.

Click for more on Artificial Sweetener

"What this study is showing is that we need to look back at the environmental factors, because what we see today is not only what's happening today, but what happened two generations ago and maybe even longer," said co-author Pradeep Bhide, the Jim, and Betty Ann Rodgers Eminent Scholar Chair of Developmental Neuroscience in the Department of Biomedical Sciences.

The study came about, in part, because of previous research from the Bhide Lab on the transgenerational effects of nicotine on mice.

The research showed temporary, or epigenetic, changes in mouse sperm cells. Unlike genetic changes (mutations), epigenetic changes are reversible and don't change the DNA sequence; however, they can change how the body reads a DNA sequence.

"We were working on the effects of nicotine on the same type of model," Bhide said. "The father smokes. What happened to the children?"

The US Food and Drug Administration (USFDA) approved aspartame as a sweetener in 1981. Today, nearly 5,000 metric tons are produced each year.

When consumed, aspartame becomes aspartic acid, phenylalanine, and methanol, all of which can have potent effects on the central nervous system.

Led by doctoral candidate Sara Jones, the study involved providing mice with drinking water containing aspartame at approximately 15% of the FDA-approved maximum daily human intake.

The dosage, equivalent to six to eight 8-ounce cans of diet soda a day for humans, continued for 12 weeks in a study spanning four years.

Pronounced anxiety-like behavior was observed in the mice through a variety of maze tests across multiple generations descending from the aspartame-exposed males.

"It was such a robust anxiety-like trait that I don't think any of us anticipated we would see," Jones said. "It was completely unexpected.

Usually, you see subtle changes."

When given diazepam, a drug used to treat anxiety disorder in humans, mice in all generations ceased to show anxiety-like behavior.

This study's researchers are planning another publication that will focus on how aspartame affected memory.

Future research will identify the molecular mechanisms that influence the transmission of aspartame's effects across generations.

What is Normal Blood Sugar by Age? Know The Range

Indian scientists discover new Anti-Cancer Agent

Skin diseases: Avoid self-medication, advice experts

BF-7: क्या वैक्सीन लगवा चुके लोगों को भी है Covid के नए वैरिएंट से खतरा? Dr. Trehan answers

Govt to provide 450 types of medical tests free of cost from Jan 1

Google’s this Tool can easily understand your Doctor’s bad handwriting

10 things: Must keep in First Aid Box: Very useful in emergency

Blood को पतला करने के लिए इन Foods को करे diet में शामिल: No medicine

Replace your Cosmetic products with these 7 harmless natural things

Fever? Avoid self-medication, say Experts
https://thehealthmaster.com/2023/01/14/artificial-sweetener-in-diet-products-linked-to-anxiety-must-read/
Govt Job: For Pharma Research Associate at BITS
The BITS BioCyTiH Foundation (henceforth The Foundation) is a Section 8 non-profit company hosted by BITS Pilani under the National Mission of Interdisciplinary Cyber-Physical Systems (NM-ICPS) of Government of India (GOI).

The mandate of the company is to fashion a platform that would foster translational research, innovation, skill development and training in areas of bio-cyber-physical systems (Bio-CPS) related to healthcare, agriculture, water and environment.

The aim is to build state of the art national facilities across three campuses of BITS Pilani (viz. Pilani, Goa and Hyderabad), extend support to researchers, innovators and startups building products and solutions.

As part of the infrastructure a Bio-CPS focused incubator is planned to be built and operationalized which will house innovators and startups.

Post : Research Associate (Post-Doctoral Fellow)

Project Title & DetailsMethylated cfDNA as a pathological biomarker for the development of a CRISPR/Cas based molecular diagnostic tool

Details : Chronic diseases are estimated to kill almost 41 million people a year worldwide, making up seven out of ten deaths globally.

Of these deaths, approximately 17 million are classed as premature, with people dying significantly younger than expected on average (WHO, 2020).

Some of the most common chronic diseases include Chronic Kidney Disease (CKD), Cardio-vascular diseases (CVDs), and Type 2 Diabetes Mellitus (T2DM).

In addition, in some cases, the patient could be diagnosed with all of these diseases. However, the management of these diseases is possible if the patient could be treated at an early stage.

Biosensors are the tools that can diagnose any infection/disease within the body by analysing molecular biomarkers such as nucleic acids and proteins.

Literature evidence suggests the association of disease progression with the changes in the cell-free DNA (cfDNA) present in the blood, serum, and urine thus it could reflect the pathological conditions.

CRISPR biosensors have been reported for their ability to detect nucleic acid at the femtomole level with high accuracy and precision and therefore could be a potential method to detect the aforementioned nucleic acid biomarkers.

The project involves the genetic interrogation of the cfDNA and its correlation with the disease progression and to utilize the CRISPR system for developing a biosensor that could detect chronic diseases at an early stage.

Duration : 12 months or till project duration, whichever is earlier

Job Description and Responsibilities

The candidate will be responsible for lab activities related to the above project.

The candidate will be responsible for 90% core research activities, including scientific logistics (grant writing, lab and grant management, etc.), 10% with Ph.D. scholars (support for young researchers)

Qualification and Experience

Essential: The applicant should hold a Ph.D. Degree or have submitted thesis in Pharmaceutical Sciences, Pharmacology, Biotechnology, Life Sciences or related field.

Candidates who are on the verge of their thesis submission can also apply. Their joining will be subjected to the fulfillment of the essential requirements.

Salary47000/-p.m. + applicable HRA for candidates with thesis submitted49000/-p.m. + applicable HRA for candidates with Ph. D degree awarded54000/-p.m. + applicable HRA for candidates with two years of post Ph. D experience

Project PI : Prof. Deepak Chitkara

Primary Location of the position : BITS Pilani, Pilani Campus, Vidya Vihar, Pilani, Rajasthan

Apply Online

Govt Job: For M.Pharm, B.Pharm at NPPA

Govt Job: For Pharmacists under Ministry of Defence

Govt Job: For M.Pharm, M.Sc for IMR Research Project at CSMCARI

Govt Job: For Lecturers in Pharmacy institute under ME&RD

Govt Job: For Pharma professionals as Consultant at ICMR – Pa y Rs. 70k pm

Govt Job: For the post of Director at CDTL, CDSCO
https://thehealthmaster.com/2023/01/14/govt-job-for-pharma-research-associate-at-bits/
Govt Job: For Pharma Research Associate at BITS
The BITS BioCyTiH Foundation (henceforth The Foundation) is a Section 8 non-profit company hosted by BITS Pilani under the National Mission of Interdisciplinary Cyber-Physical Systems (NM-ICPS) of Government of India (GOI).

The mandate of the company is to fashion a platform that would foster translational research, innovation, skill development and training in areas of bio-cyber-physical systems (Bio-CPS) related to healthcare, agriculture, water and environment.

The aim is to build state of the art national facilities across three campuses of BITS Pilani (viz. Pilani, Goa and Hyderabad), extend support to researchers, innovators and startups building products and solutions.

As part of the infrastructure a Bio-CPS focused incubator is planned to be built and operationalized which will house innovators and startups.

Post : Research Associate (Post-Doctoral Fellow)

Project Title & DetailsMethylated cfDNA as a pathological biomarker for the development of a CRISPR/Cas based molecular diagnostic tool

Details : Chronic diseases are estimated to kill almost 41 million people a year worldwide, making up seven out of ten deaths globally.

Of these deaths, approximately 17 million are classed as premature, with people dying significantly younger than expected on average (WHO, 2020).

Some of the most common chronic diseases include Chronic Kidney Disease (CKD), Cardio-vascular diseases (CVDs), and Type 2 Diabetes Mellitus (T2DM).

In addition, in some cases, the patient could be diagnosed with all of these diseases. However, the management of these diseases is possible if the patient could be treated at an early stage.

Biosensors are the tools that can diagnose any infection/disease within the body by analysing molecular biomarkers such as nucleic acids and proteins.

Literature evidence suggests the association of disease progression with the changes in the cell-free DNA (cfDNA) present in the blood, serum, and urine thus it could reflect the pathological conditions.

CRISPR biosensors have been reported for their ability to detect nucleic acid at the femtomole level with high accuracy and precision and therefore could be a potential method to detect the aforementioned nucleic acid biomarkers.

The project involves the genetic interrogation of the cfDNA and its correlation with the disease progression and to utilize the CRISPR system for developing a biosensor that could detect chronic diseases at an early stage.

Duration : 12 months or till project duration, whichever is earlier

Job Description and Responsibilities

The candidate will be responsible for lab activities related to the above project.

The candidate will be responsible for 90% core research activities, including scientific logistics (grant writing, lab and grant management, etc.), 10% with Ph.D. scholars (support for young researchers)

Qualification and Experience

Essential: The applicant should hold a Ph.D. Degree or have submitted thesis in Pharmaceutical Sciences, Pharmacology, Biotechnology, Life Sciences or related field.

Candidates who are on the verge of their thesis submission can also apply. Their joining will be subjected to the fulfillment of the essential requirements.

Salary47000/-p.m. + applicable HRA for candidates with thesis submitted49000/-p.m. + applicable HRA for candidates with Ph. D degree awarded54000/-p.m. + applicable HRA for candidates with two years of post Ph. D experience

Project PI : Prof. Deepak Chitkara

Primary Location of the position : BITS Pilani, Pilani Campus, Vidya Vihar, Pilani, Rajasthan

Apply Online

Govt Job: For M.Pharm, B.Pharm at NPPA

Govt Job: For Pharmacists under Ministry of Defence

Govt Job: For M.Pharm, M.Sc for IMR Research Project at CSMCARI

Govt Job: For Lecturers in Pharmacy institute under ME&RD

Govt Job: For Pharma professionals as Consultant at ICMR – Pa y Rs. 70k pm

Govt Job: For the post of Director at CDTL, CDSCO
https://thehealthmaster.com/2023/01/14/govt-job-for-pharma-research-associate-at-bits/
NPPA revised Retail Price of 93 scheduled formulations: January 2023
Download NPPA notification No. S.O. S.O. 87(E) dt 06-01-2023, the link is given below: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, has fixed the retail price of 4 scheduled formulations vide vide S.O. 87(E) dt 06-01-2023 based on the decision of 106th Authority meeting dated 30.12.2022

Download notification No. S.O. 87(E) dt 06-01-2023

This price fixation followed the decision of the 106th Authority meeting on December 30, 2022.

In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued by the Government of India the Ministry of Chemicals and Fertilizers and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No SO1499(E) dated 30th March, 2022 in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (5) of the table herein below as ceiling price exclusive of goodsand services tax applicable, if any, in respect of the Scheduled formulation specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

Table

Sl. No.Name of the Scheduled Formulation  Dosage form and strength  UnitCeiling Price (Rs.)(1)(2)(3)(4)(5)1SulfasalazineTablet 500 mg1 Tablet4.212DigoxinTablet 0.25mg1 Tablet1.193EthambutolTablet 600mg1 Tablet3.644PhenytoinTablet 300mg1 Tablet4.89  5Atazanavir (A) +Ritonavir(B)Tablet 300mg(A) + Tablet 100mg(B)  1 Tablet  89.036CeftriaxonePowder for Injection 500 mg1 Vial44.847CeftriaxonePowder for Injection 250 mg1 Vial25.288CeftriaxonePowder for Injection 1000mg1 Vial55.649CeftriaxonePowder for Injection 2000mg1 Vial123.1810CefotaximePowder for Injection 250 mg1 Vial15.8011CefotaximePowder for Injection 500 mg1 Vial21.7412CefotaximePowder for Injection 1000mg1 Vial35.64  13Piperacillin (A) +Tazobactam(B)Powder for Injection 1000mg(A)+125mg(B)  1 Vial  88.88  14Piperacillin (A) +Tazobactam(B)Powder for Injection 2000mg(A)+250mg(B)  1 Vial  170.83  15Piperacillin (A) +Tazobactam(B)Powder for Injection 4000mg(A)+500mg(B)  1 Vial  356.2116AmpicillinPowder for Injection 500 mg1 Vial12.7117MetoprololTablet 25mg1 Tablet3.7518MetoprololTablet 50mg1 Tablet5.21

19PropranololTablet 40mg1 Tablet2.8720FluconazoleTablet 200mg1 Tablet15.5721EthambutolTablet 800mg1 Tablet4.4222PyrazinamideTablet 1000mg1 Tablet9.3923PyrazinamideTablet 500mg1 Tablet4.3624PyrazinamideTablet 750mg1 Tablet6.4325PhenobarbitoneTablet 30mg1 Tablet1.1726AmiodaroneTablet 200mg1 Tablet10.2727EthambutolTablet 400mg1 Tablet2.3328FluconazoleTablet 100mg1 Tablet6.8029AzathioprineTablet 50mg1 Tablet10.0430AllopurinolTablet 100mg1 Tablet1.6931PropranololTablet 10mg1 Tablet1.1732HydroxychloroquineTablet 200mg1 Tablet5.6733CarbimazoleTablet 10mg1 Tablet3.8034CefiximeTablet 200mg1 Tablet8.7235ImatinibTablet 100mg1 Tablet62.2136TamoxifenTablet 20mg1 Tablet2.6337TamoxifenTablet 10mg1 Tablet1.9738L-AsparaginasePowder for Injection 5000 KU1 Vial922.94  39  L-AsparaginasePowder for Injection 10000KU  1 Vial  1523.0340DacarbazinePowder for Injection 200mg1 Vial340.4641MefloquineTablet 250 mg1 Tablet46.5242ThalidomideCapsule 50 mg1 Capsule27.7943ThalidomideCapsule 100mg1 Capsule55.3144ClonazepamTablet 0.25mg1 Tablet1.80

45ClonazepamTablet 0.5mg1 Tablet3.0846ClonazepamTablet 1mg1 Tablet4.2547ClozapineTablet 25mg1 Tablet2.4848ClozapineTablet 50mg1 Tablet4.6349ClozapineTablet 100 mg1 Tablet7.5450MetronidazoleTablet 200mg1 Tablet0.7351MetronidazoleTablet 400mg1 Tablet1.3652HydroxyureaCapsule 500mg1 Capsule10.8153IbuprofenTablet 200mg1 Tablet0.6354AcetazolamideTablet 250mg1 Tablet3.6255CiprofloxacinTablet 250mg1 tablet1.9656SalbutamolTablet 4 mg1 Tablet0.1957SalbutamolTablet 2 mg1 Tablet0.1658MetoclopramideTablet 10mg1 Tablet1.20  59Amoxicillin (A) +Clavulanic acid (B)Tablet 500 mg (A) + 125 mg (B)  1 Tablet  16.3260DocetaxelPowder for Injection 20mg1 Vial2558.1461ClopidogrelTablet 75mg1 Tablet5.9462HydrocortisonePowder for Injection 100mg1 Vial39.9563GemcitabinePowder for Injection 1000mg1 Vial4987.6564MethotrexateTablet 10mg1 tablet11.8565MethotrexateTablet 2.5mg1 tablet4.7466DiltiazemTablet 60mg1 Tablet4.8767AmiodaroneTablet 100mg1 Tablet5.4868Dom1idoneTablet 10mg1 Tablet2.0669QuinineTablet 300 mg1 Tablet5.0470EnalaprilTablet 5mg1 Tablet3.3071EnalaprilTablet 2.5mg1 Tablet1.95

72AcyclovirTablet 400mg1 Tablet12.1873AcyclovirTablet 200mg1 Tablet6.7974RifampicinCapsule 450mg1 Capsule5.06  75Zidovudine (A) +Lamivudine(B)  Tablet 300mg(A)+150mg(B)  1 Tablet  18.8176PrimaquineTablet 7.5mg1 Tablet2.1277NitrofurantoinTablet 100 mg1 Tablet7.2378CiprofloxacinTablet 500mg1 tablet3.7979OndansetronTablet 8 mg1 Tablet7.9480GriseofulvinTablet 250mg1 Tablet1.5881EscitalopramTablet 5mg1 Tablet4.4882EscitalopramTablet 10mg1 Tablet8.0383EscitalopramTablet 20mg1 Tablet12.8184GemcitabinePowder for Injection 200 mg1 Vial1159.2185CeftazidimePowder for Injection 1000mg1 Vial202.4786DiclofenacTablet 50mg1 Tablet1.8387CarbamazepineTablet 200mg1 Tablet1.40  88Amoxicillin (A) + Clavulanic acid (B)Powder for Injection 1 g (A) +200mg (B)  1 Vial  125.4489BisacodylTablet 5mg1 Tablet1.0490PantoprazoleInjection 40mg1 Vial45.00  91Ethinylestradiol (A)+ Levonorgestrel (B)Tablet 0.03mg(A) + Tablet 0.15mg(B)  1 Tablet  2.8392NorethisteroneTablet 5mg1 Tablet4.8193CarbimazoleTablet 5mg1 Tablet1.95

Click for more articles on NPPA

Note:(a) All manufacturers of scheduled formulation, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any.

(b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above-said table.

Click for more articles on DPCO 2013

(d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the DPCO 2013.

The manufacturer shall issue a price list in Form–V from the date of the Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner to be easily accessible to any person wishing to consult the same.

(f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule II of the DPCO, 2013.

(g) The manufacturers of above said scheduled formulations shall furnish quarterly returns to the NPPA, in respect of the production/import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS.

Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the DPCO 2013 read with Essential Commodities Act, 1955.

(i) Consequent to the issue of the ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above-said date of notification, stand(s) superseded.

Latest on National Pharmaceutical Pricing Authority (NPPA)

Latest notifications – DPCO / NPPA

NPPA updated price lists: Download

Latest Notifications: EC Act (Essential Commodities Act)

FAQs – On DPCO: Drugs (Prices Control) Order, 2013

National List of Essential Medicines (NLEM)

NPPA fixes Retail Price of 4 scheduled formulations: January 2023

NPPA fixes retail price of 36 formulations: January 2023

NPPA fixes Retail Price of 10 formulations: December 2022

NPPA fixes Retail Price of 12 scheduled formulations: December 2022

NPPA revises Retail Price of 107 scheduled formulations: December 2022

NPPA fixes Retail Price of one formulation: November 2022

USFDA issues warning letter to Sun Pharma for its Gujarat plant

Tramadol: 3 Pharmaceutical Companies under scanner

NMC allows foreign medical graduates to finish internship in India

NABL suspends accreditation of 80 laboratories

NPPA fixes Retail Price of 4 scheduled formulations: January 2023

Medical Oxygen plants to be put on digital map

JIPMER: Nursing Officer 2022 result declared, Download

List of approved FDCs (Fixed Dose Combinations) Updated

List of approved New Drugs Updated

Latest Notifications regarding Pharmaceutical
https://thehealthmaster.com/2023/01/14/nppa-revised-retail-price-of-93-scheduled-formulations-january-2023/
USFDA issues warning letter to Sun Pharma for its Gujarat plant
The US Food and Drug Administration (USFDA) has issued a warning letter to Sun Pharmaceutical Limited about manufacturing errors at its Gujarat-based plant, including failing to follow the necessary documented procedures intended to avoid microbiological contamination of drug goods.

From April 26 to May 9, 2022, the manufacturing facility was under inspection by the health authority.

The Halol plant, which creates finished pharmaceutical products, was found to have a number of violations, according to a warning letter from the USFDA.

Click for more articles on USFDA

"This warning letter summarizes substantial violations of Current Good Manufacturing Practice (CGMP) standards for finished pharmaceuticals," the USFDA wrote in the warning letter.

In its other warning letter to the Mumbai-based company, the USFDA cited the drug company's failure to establish and adhere to appropriate written procedures that are intended to prevent microbiological contamination of drug products that are claimed to be sterile, and that include validation of all aseptic and sterilisation processes.

Warning letter further states:

- Your drug goods are adulterated because your manufacturing, processing, packing, or holding processes, facilities, or controls don't follow CGMP guidelines.

- Your firm failed to undertake activities within clearly defined zones of suitable size and to have separate or defined areas or such other control measures necessary to prevent contamination r mix-ups in aseptic processing facilities.

- Your ISO 5 cleanroom spaces used for aseptic compounding and filling were inadequately protected and poorly built.

- Sterile drug goods are exposed in the ISO 5 region, making them susceptible to contamination.

- Your firm failed to employ equipment that is of proper design, adequate size, and suitably positioned to facilitate operations for its intended use, as well as for its cleaning and maintenance.

- Significant findings in this letter demonstrate that your company does not operate an effective quality system in accordance with CGMP.

Other warning letters by USFDA

USFDA issues warning letter to Sun Pharma for Halol facility

USFDA issues warning letter to Glenmark’s Goa facility

USFDA issues warning letter to Lupin

USFDA issues warning letter to Lupin API plant

USFDA issues warning letter to Aurobindo Pharma for manufacturing lapses at API plant

USFDA gives warning letter to Aurobindo Pharma for API facility

Tramadol: 3 Pharmaceutical Companies under scanner

NMC allows foreign medical graduates to finish internship in India

NABL suspends accreditation of 80 laboratories

NPPA fixes Retail Price of 4 scheduled formulations: January 2023

Medical Oxygen plants to be put on digital map

JIPMER: Nursing Officer 2022 result declared, Download

Sale of coronary stents: High Court seeks stand of Centre and NPPA

List of approved FDCs (Fixed Dose Combinations) Updated

List of approved New Drugs Updated

Latest Notifications regarding Pharmaceutical
https://thehealthmaster.com/2023/01/14/usfda-issues-warning-letter-to-sun-pharma-for-its-gujarat-plant/
USFDA issues warning letter to Sun Pharma for its Gujarat plant
The US health regulator has warned Sun Pharmaceutical Limited for manufacturing errors at its Gujarat-based plant, including failing to follow the necessary documented procedures intended to avoid microbiological contamination of drug goods.

From April 26 to May 9, 2022, the manufacturing facility was under inspection by the health authority.

The Halol plant, which creates finished pharmaceutical products, was found to have a number of violations, according to a warning letter from the US Food and Drug Administration (USFDA).

"This warning letter summarises substantial violations of Current Good Manufacturing Practice (CGMP) standards for finished pharmaceuticals," the USFDA wrote in the warning letter.

The USFDA cited the drug company's failure to establish and adhere to appropriate written procedures that are intended to prevent microbiological contamination of drug products that are claimed to be sterile, and that include validation of all aseptic and sterilisation processes, in its other warning letter to the Mumbai-based company.

Warning letter further states:

- Your drug goods are adulterated because your manufacturing, processing, packing, or holding processes, facilities, or controls don't follow CGMP guidelines.

- Your firm failed to undertake activities within clearly defined zones of suitable size and to have separate or defined areas or such other control measures necessary to prevent contamination r mix-ups in aseptic processing facilities.

- Your ISO 5 cleanroom spaces used for aseptic compounding and filling were inadequately protected and poorly built.

- Sterile drug goods are exposed in the ISO 5 region, making them susceptible to contamination.

- Your firm failed to employ equipment that is of proper design, adequate size, and suitably positioned to facilitate operations for its intended use, as well as for its cleaning and maintenance.

- Significant findings in this letter demonstrate that your company does not operate an effective quality system in accordance with CGMP.

Tramadol: 3 Pharmaceutical Companies under scanner

NMC allows foreign medical graduates to finish internship in India

NABL suspends accreditation of 80 laboratories

NPPA fixes Retail Price of 4 scheduled formulations: January 2023

Medical Oxygen plants to be put on digital map

JIPMER: Nursing Officer 2022 result declared, Download

Sale of coronary stents: High Court seeks stand of Centre and NPPA

List of approved FDCs (Fixed Dose Combinations) Updated

List of approved New Drugs Updated

Latest Notifications regarding Pharmaceutical
https://thehealthmaster.com/2023/01/14/usfda-issues-warning-letter-to-sun-pharma-for-its-gujarat-plant/

Friday, January 13, 2023

NABL
National Accreditation Board for Testing and Calibration Laboratories

Download NABL releases: National Accreditation Board for Testing and Calibration Laboratories (NABL) is an accreditation body, with its accreditation system established in accordance with ISO/ IEC 17011. “Conformity Assessment –Requirements for Accreditation bodies accrediting conformity assessment bodies.” NABL provides voluntary accreditation services to:

Picture: Pixabay

Testing laboratories in accordance with ISO/ IEC 17025 ‘General Requirements for the Competence of Testing and Calibration Laboratories’ 

Calibration laboratories in accordance with ISO/ IEC 17025 ‘General Requirements for the Competence of Testing and Calibration Laboratories’ 

Medical testing laboratories in accordance with ISO 15189 ‘Medical laboratories -Requirements for quality and competence’ 

Proficiency Testing Providers (PTP) in accordance with ISO/IEC 17043 “Conformity assessment — General requirements for proficiency testing” and 

Reference material producers (RMP) in accordance with ISO 17034 “General requirements for the competence of reference material producers”. 

NABL Release

2022

NABL dt 23-11-2022 NABL 100B Accreditation Process & Procedure

NABL-dt-23-11-2022-NABL-100B-Accreditation-Process-Procedure

NABL dt 23-11-2022 NABL 100A General Information Brochure

NABL-dt-23-11-2022-NABL-100A-General-Information-Brochure

NABL 17-05-2022 Guidelines for improving quality and standards of laboratories

NABL-17-05-2022-Guidelines-for-improving-quality-and-standards-of-laboratories

2021

NABL dt 25-10-2021 - NABL 164 - Guidelines for Interlaboratory Comparison for Calibration Laboratories where Formal PT Programs are not available

NABL-dt-25-10-2021-NABL-164-Guidelines-for-Interlaboratory-Comparison-for-Calibration-Laboratories-where-Formal-PT-Programs-are-not-available

NABL dt 24-08-21 - NABL 136 - Specific Criteria for Accreditation of Quality Assurance Testing Facilities for Diagnostic Radiology X-Ray Equipment

NABL-dt-24-08-21-NABL-136-Specific-Criteria-for-Accreditation-of-Quality-Assurance-Testing-Facilities-for-Diagnostic-Radiology-X-Ray-Equipment

NABL dt 01-06-2021 - NABL 126 - Specific Criteria for Calibration of Medical Devices

NABL-dt-01-06-2021-NABL-126-Specific-Criteria-for-Calibration-of-Medical-Devices

Click for more articles on NABL

List of NABL Accredited Testing Laboratories

NABL Accredited Laboratories for Biological Testing of various parts of Medical Devices as per ISO 10993

NABL-Accredited-Laboratories-for-Biological-Testing-of-various-parts-of-Medical-Devices-as-per-ISO-10993

NABL Accredited Laboratories for Calibration of Medical Equipment

NABL-Accredited-Laboratories-for-Calibration-of-Medical-Equipment

NABL Accredited Laboratories for testing of Endotoxin in Surgical and Medical Items

NABL-Accredited-Laboratories-for-testing-of-Endotoxin-in-Surgical-and-Medical-Items

NABL Accredited Laboratories for testing of Gloves (Mechanical and Chemical tests)

NABL-Accredited-Laboratories-for-testing-of-Gloves-Mechanical-and-Chemical-tests

Click for more articles on NABL

NABL Accredited Laboratories for testing of Masks (Protective properties and requirements)

NABL-Accredited-Laboratories-for-testing-of-Masks-Protective-properties-and-requirements

NABL Accredited Laboratories for testing of PPE kits, Coverall, Medical Protective clothing

NABL-Accredited-Laboratories-for-testing-of-PPE-kits-Coverall-Medical-Protective-clothing

NABL Accredited Laboratories for testing of Pyrogen in Medical Devices

NABL-Accredited-Laboratories-for-testing-of-Pyrogen-in-Medical-Devices

NABL Accredited Laboratories for testing of Sanitizer and Disinfectants

NABL-Accredited-Laboratories-for-testing-of-Sanitizer-and-Disinfectants

NABL Accredited Laboratories for testing of Ventilators, Pulse Oximeter & Oxygen concentrator

NABL-Accredited-Laboratories-for-testing-of-Ventilators-Pulse-Oximeter-Oxygen-concentrator

Commercial Testing Laboratories

Govt Laboratories

List of Laboratory instruments

Licensing procedure for Medical devices

Latest Notifications: Medical Devices
https://thehealthmaster.com/notifications/testing-laboratories-notifications/nabl/
NABL
National Accreditation Board for Testing and Calibration Laboratories

Download NABL releases: National Accreditation Board for Testing and Calibration Laboratories (NABL) is an accreditation body, with its accreditation system established in accordance with ISO/ IEC 17011. “Conformity Assessment –Requirements for Accreditation bodies accrediting conformity assessment bodies.” NABL provides voluntary accreditation services to:

Picture: Pixabay

Testing laboratories in accordance with ISO/ IEC 17025 ‘General Requirements for the Competence of Testing and Calibration Laboratories’ 

Calibration laboratories in accordance with ISO/ IEC 17025 ‘General Requirements for the Competence of Testing and Calibration Laboratories’ 

Medical testing laboratories in accordance with ISO 15189 ‘Medical laboratories -Requirements for quality and competence’ 

Proficiency Testing Providers (PTP) in accordance with ISO/IEC 17043 “Conformity assessment — General requirements for proficiency testing” and 

Reference material producers (RMP) in accordance with ISO 17034 “General requirements for the competence of reference material producers”. 

NABL Release

2022

NABL dt 23-11-2022 NABL 100B Accreditation Process & Procedure

NABL-dt-23-11-2022-NABL-100B-Accreditation-Process-Procedure

NABL dt 23-11-2022 NABL 100A General Information Brochure

NABL-dt-23-11-2022-NABL-100A-General-Information-Brochure

NABL 17-05-2022 Guidelines for improving quality and standards of laboratories

NABL-17-05-2022-Guidelines-for-improving-quality-and-standards-of-laboratories

2021

NABL dt 25-10-2021 - NABL 164 - Guidelines for Interlaboratory Comparison for Calibration Laboratories where Formal PT Programs are not available

NABL-dt-25-10-2021-NABL-164-Guidelines-for-Interlaboratory-Comparison-for-Calibration-Laboratories-where-Formal-PT-Programs-are-not-available

NABL dt 24-08-21 - NABL 136 - Specific Criteria for Accreditation of Quality Assurance Testing Facilities for Diagnostic Radiology X-Ray Equipment

NABL-dt-24-08-21-NABL-136-Specific-Criteria-for-Accreditation-of-Quality-Assurance-Testing-Facilities-for-Diagnostic-Radiology-X-Ray-Equipment

NABL dt 01-06-2021 - NABL 126 - Specific Criteria for Calibration of Medical Devices

NABL-dt-01-06-2021-NABL-126-Specific-Criteria-for-Calibration-of-Medical-Devices

List of NABL Accredited Testing Laboratories

NABL Accredited Laboratories for Biological Testing of various parts of Medical Devices as per ISO 10993

NABL-Accredited-Laboratories-for-Biological-Testing-of-various-parts-of-Medical-Devices-as-per-ISO-10993

NABL Accredited Laboratories for Calibration of Medical Equipment

NABL-Accredited-Laboratories-for-Calibration-of-Medical-Equipment

NABL Accredited Laboratories for testing of Endotoxin in Surgical and Medical Items

NABL-Accredited-Laboratories-for-testing-of-Endotoxin-in-Surgical-and-Medical-Items

NABL Accredited Laboratories for testing of Gloves (Mechanical and Chemical tests)

NABL-Accredited-Laboratories-for-testing-of-Gloves-Mechanical-and-Chemical-tests

NABL Accredited Laboratories for testing of Masks (Protective properties and requirements)

NABL-Accredited-Laboratories-for-testing-of-Masks-Protective-properties-and-requirements

NABL Accredited Laboratories for testing of PPE kits, Coverall, Medical Protective clothing

NABL-Accredited-Laboratories-for-testing-of-PPE-kits-Coverall-Medical-Protective-clothing

NABL Accredited Laboratories for testing of Pyrogen in Medical Devices

NABL-Accredited-Laboratories-for-testing-of-Pyrogen-in-Medical-Devices

NABL Accredited Laboratories for testing of Sanitizer and Disinfectants

NABL-Accredited-Laboratories-for-testing-of-Sanitizer-and-Disinfectants

NABL Accredited Laboratories for testing of Ventilators, Pulse Oximeter & Oxygen concentrator

NABL-Accredited-Laboratories-for-testing-of-Ventilators-Pulse-Oximeter-Oxygen-concentrator

Commercial Testing Laboratories

Govt Laboratories

List of Laboratory instruments

Licensing procedure for Medical devices

Latest Notifications: Medical Devices
https://thehealthmaster.com/notifications/testing-laboratories-notifications/nabl/
NPPA fixes Retail Price of 4 scheduled formulations: January 2023
Download NPPA notification No. S.O. S.O. 88(E) dt 06-01-2023, the link is given below: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, has fixed the retail price of 4 scheduled formulations vide vide S.O. 88(E) dt 06-01-2023 based on the decision of 106th Authority meeting dated 30.12.2022

Download notification No. S.O. 88(E) dt 06-01-2023

This price fixation followed the decision of the 106th Authority meeting on December 30, 2022.

In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the Scheduled formulation specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

Table

-

Sl. No.Name of the Scheduled FormulationDosage form and strength  UnitCeiling Price (Rs.)(1)(2)(3)(4)(5)1.Buprenorphine (A) +Naloxone (B)Tablet (Sub-lingual) 2mg(A)+0.5mg(B)  1 Tablet  32.982.Buprenorphine (A) +Naloxone (B)Tablet (Sub-lingual) 0.4mg(A)+0.1mg(B)  1 Tablet  10.543.BuprenorphineTablet (Sub-lingual)0.4mg1 Tablet8.41    4.Tenofovir Alafenamide Fumarate (TAF)    Tablet 25mg    1 Tablet    43.59

Click for more articles on NPPA

Note:(a) All manufacturers of scheduled formulation, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any.

(b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above-said table.

Click for more articles on DPCO 2013

(d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the DPCO 2013. The manufacturer shall issue a price list in Form–V from the date of the Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner to be easily accessible to any person wishing to consult the same.

(f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule II of the DPCO, 2013.

(g) The manufacturers of above said scheduled formulations shall furnish quarterly returns to the NPPA, in respect of the production/import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and/or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

(h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the DPCO 2013 read with Essential Commodities Act, 1955.

(i) Consequent to the issue of the ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above-said date of notification, stand(s) superseded.

Latest on National Pharmaceutical Pricing Authority (NPPA)

Latest notifications – DPCO / NPPA

NPPA updated price lists: Download

Latest Notifications: EC Act (Essential Commodities Act)

FAQs – On DPCO: Drugs (Prices Control) Order, 2013

National List of Essential Medicines (NLEM)

NPPA fixes retail price of 36 formulations: January 2023

NPPA fixes Retail Price of 10 formulations: December 2022

NPPA fixes Retail Price of 12 scheduled formulations: December 2022

NPPA revises Retail Price of 107 scheduled formulations: December 2022

NPPA fixes Retail Price of one formulation: November 2022

NPPA fixes Retail Price of 40 formulations: November 2022

Medical Oxygen plants to be put on digital map

NPPA fixes retail price of 36 formulations: January 2023

JIPMER: Nursing Officer 2022 result declared, Download

USFDA gives approval for Febuxostat tablets

Sale of coronary stents: High Court seeks stand of Centre and NPPA

IPC publishes draft monograph revision proposals

High demand for Indian generic drugs in China

List of approved FDCs (Fixed Dose Combinations) Updated

List of approved New Drugs Updated

Latest Notifications regarding Pharmaceutical
https://thehealthmaster.com/2023/01/13/nppa-fixes-retail-price-of-4-scheduled-formulations-january-2023/